Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | GRK5 | P34947 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13195724 | 0.84 | SMN1; SMN2 (0.45) | PKMSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL27312546 | 0.81 | SMN1; SMN2 (0.61) | PKMSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL1857212 | 0.79 | PKM (0.41) | PKMSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL14376855 | 0.79 | SMN1; SMN2 (0.46) | PKMSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL8340619 | 0.78 | SMN1; SMN2 (0.44) | PKMSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL9202274 | 0.76 | PKM (0.47) | PKMSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL2386652 | 0.75 | PKM (0.66) | PKMSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL18282576 | 0.73 | PKM (0.48) | PKMSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL25170908 | 0.72 | PKM (0.47) | PKMSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL14357647 | 0.72 | MAPT (0.48) | PKMSMN1; SMN2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-9422250-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | PKM 1984/4885SMN1; SMN2 3359/4885NPC1 1081/4885 |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | PKM 1984/4885SMN1; SMN2 3359/4885NPC1 1081/4885 |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | PKM 1984/4885SMN1; SMN2 3359/4885NPC1 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.